




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>4</sup> : C07D 215/06, 215/08, 215/12 A61K 31/47, A23K 3/00	A1	(11) International Publication Number: WO 88/ 08420 (43) International Publication Date: 3 November 1988 (03.11.88)
(21) International Application Number: PCT/HU88/00026 (22) International Filing Date: 22 April 1988 (22.04.88) (31) Priority Application Numbers: 1740/87 1740/87 (32) Priority Dates: 22 April 1987 (22.04.87) 11 April 1988 (11.04.88) (33) Priority Country: HU (71) Applicant (for all designated States except US): MATE- RIÁL VEGYIPARI KISSZÖVETKEZET [HU/HU]; Ócsai ut 5260/78 hrsz., H-1209 Budapest (HU). (72) Inventors; and (75) Inventors/Applicants (for US only) : SZVOBODA, János [HU/HU]; Wesselényi u. 146, H-1204 Budapest (HU). ROZSNYAI, Tamás [HU/HU]; Visegrádi u. 13, H- 1132 Budapest (HU). SZENTE, József [HU/HU]; Dózsa Gy. u. 24, H-2340 Kiskunlacháza (HU). ME- LOVITS, László [HU/HU];		Gábor Á. u. 13, H-1182 Budapest (HU). ÖTVÖS, Im- re [HU/HU]; Elvira u. 2780 hrsz., H-1209 Budapest (HU). LÉGRÁDI, Ilona [HU/HU]; Wagner u. 7, H- 1209 Budapest (HU). (74) Agent: PATENTBUREAU DANUBIA; Bajcsy-Zsi- linszky ut 16, H-1051 Budapest V (HU). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), BG, BR, CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, RO, SE (European patent), SU, US.  Published With international search report.
(54) Title: CONDENSATION PRODUCTS OF 2,2,4-TRIMETHYL-1,2-DIHYDRO-QUINOLINE AND OXO COM- POUNDS AND DERIVATIVES THEREOF.		



## (57) Abstract

There are provided new compounds of general formula (I) obtained by the condensation of 2,2,4-trimethyl-1,2-dihydro-quinoline or salts thereof with an oxo derivative of the general formula  $R_1R_2CO$ , wherein  $R_1$  stands for optionally substituted  $C_{1-4}$  alkyl and  $R_2$  stands for optionally substituted  $C_{1-2}$  alkyl, X stands for hydrogen or  $SO_3Me$ , wherein Me stands for hydrogen, alkali or alkali earth metal ion, Y stands for hydrogen or acyl. The new compounds can be used as antioxidants, and particularly for increasing coccidiostatic effect.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

CONDENSATION PRODUCTS OF 2,2,4-TRIMETHYL-1,2-DIHYDRO-QUINOLINE  
AND OXO COMPOUNDS AND DERIVATIVES THEREOF

The present invention relates to new condensation products of 2,2,4-trimethyl-1,2-dihydro-quinoline with oxo compounds and the derivatives of same as well as a process for the preparation thereof and fodders and fodder premixes containing said compounds as well as pharmaceutical compositions containing as active ingredient the new compounds.

In the last decades the significance of the use of antioxidants has increased all over the world in various fields and consequently, the use of the antioxidants has been widely spread. Antioxidants are most often used in rubber industry and in plastic industry and in this field the highest requirement is the specific effectivity of the antioxidants and in addition a very important factor is compatibility as well as small sensibility to migration etc. The use of antioxidants in agriculture, food industry and recently in veterinary science and human therapy has increased significantly. While in rubber and plastic industry several amine and phenol type antioxidants are used for the stabilization of fodders, practically only 6-ethoxy-1,2-dihydro-2,2,4-trimethyl-quinoline (EMQ) and 2,6-di-tertiary butyl-hydroxy-toluene (BHT) have been used. The antioxidants suitable for the stabilization of fodder mixtures have to meet simultaneously several essential requirements, such as wide spectrum, low toxicity, respective no damage in optimal case. The last point of view is considered in the recommendation of

WHO/FAO Nutrition Meeting Series No. 40 A, B, C, WHO/FOD AU 67.29, according to which such antioxidants should be used for the mentioned purposes, the LD<sub>50</sub> value of which exceeds 5 g/kg body weight. It is known that either EMQ nor BHT meets this requirement. In spite of this fact these two compounds have been most accepted according to the present state of art. These two compounds are the best in meeting said complex requirements.

6,6'-methylene-bis(2,2,4-trimethyl-1,2-dihydro-quinoline) is rather used in human therapy due to its radiosensibilizing properties and it has proved to be really suitable for the stabilization of fodders as due to the extreme sensibility of its methylene group very often a colourization occurred in the fatty tissue of the animals.

The antioxidant activity of 6,6'-ethyldene-bis(2,2,4-trimethyl-1,2-dihydro-quinoline) called as XAX-M is suitable, its toxicity is low, but upon oxidation the ethyldene group is also oxidized and has a certain colourizing effect.


A further disadvantage of XAX-M prepared according to Hungarian patent specification No. 162,358 is that the product is not homogeneous chemically, but according to page 4 of the Hungarian patent specification the polycondensation degree, i.e. the number of dihydro-quinoline units changes depending upon the reaction conditions. The products obtained by acetaldehyde or higher aldehyde condensation form a mixture of condensed molecules containing 2 to 4 dihydro quinoline units. A constant composition cannot be easily ensured, although this is required by the user.

No economic and in practice applicable process has been found so far. DOS 35 40 105 relates to the same product and to its property increasing the coccidiostatic activity of known coccidiostatics.

5 The present invention was aimed to find a new compounds reserving the good antioxidant activity of the known dihydro-quinoline derivatives, but simultaneously to obtain a new product of chemically homogeneous structure being suitable for human and veterinary use increasing the activity of  
10 coccidiostatics and showing low toxicity. The new compounds should be prepared by an economic technology in high purity.

We have now found that new compounds meeting the above requirements can be prepared if 2,2,4-trimethyl-1,2-dihydro-quinoline is condensed under special reaction conditions with  
15 lower ketones and if desired the obtained compounds are sulfonated and/or acylated.

According to the present invention new compounds of the general Formula (I)



25 and acid addition salts thereof are prepared - wherein  
 $R^1$  stands for optionally substituted  $C_{1-4}$  alkyl and  
 $R^2$  stands for optionally substituted  $C_{1-2}$  alkyl,  
 $X$  stands for hydrogen or  $SO_3Me$  - wherein

Me stands for hydrogen, alkali or alkali earth metal ion,

Y stands for hydrogen or acyl.

The new compounds can be prepared by condensing aceto-  
5 anil (2,2,4-trimethyl-1,2-dihydro-quinoline) or salts thereof  
with an oxo derivative of the general Formula  $R^1R^2CO$  - wherein  
 $R^1$  and  $R^2$  are as defined above, in the presence of 1-5 %, preferably 2-3 % nitrogen containing base as a cocatalyst,  
preferably triethanol amine, pyridine or aniline and in the  
10 presence of a mineral acid, preferably 0.9-2.5 mole, preferably 1.25-1.75 mole hydrochloric acid as a catalyst related to  
the dihydro quinoline in a solvent and if desired converting  
the obtained product to acid addition salt or setting free the  
free base from the salt and if desired sulfonating and/or  
15 acylating the obtained base with sulfuric acid or oleum.

The acid addition salts can be formed with an acid, such as hydrochloric acid, hydrogen bromide or sulfuric acid, preferably hydrochloric acid.

In the meaning of  $R^1$  the alkyl groups can be straight  
20 or branched and can stand for an optionally substituted  $C_{1-4}$  alkyl, preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.butyl, preferably methyl, ethyl or isobutyl. The substituents can be selected from hydroxyl, halogen,  $C_{1-4}$  alkoxy, carboxyl and  $C_{1-4}$  alkoxy-carbonyl.  $R^2$  may preferably  
25 stand for  $C_{1-2}$  alkyl, preferably methyl, ethyl, which can be substituted with the same groups as given for  $R^1$ . X preferably stands for hydrogen or  $SO_3Me$ , wherein Me stands for alkali or alkali earth metal ion, preferably sodium, potassium or

- 5 -

calcium ion. Y preferably stands for hydrogen or an acyl group, preferably acetyl, formyl, benzoyl, particularly acetyl.

Surprisingly the use of a nitrogen containing base results in a quick condensation and thus the formation of side products is eliminated.

In the course of condensation the reaction medium is the ketone itself in an amount of 0-40 % containing preferably 10-20 % of water.

Sulfonation can be carried out by methods known per se using oleum or sulfuric acid. Acylation can be performed with known acylating agents such as acetic anhydride, acetyl chloride, benzoyl chloride, formyl chloride etc.

The reaction mixture can be worked up by filtering the salt, preferably the hydrochloride and by centrifuging and converting it into free base. A product of a purity higher than 95 % is obtained. According to another method the product is worked up together with the mother liqueur, whereafter the unreacted starting material is distilled off in vacuo and thus a product of 60-80 % purity is obtained. It shows that a pure product is obtained without crystallization. The reaction is carried out at a temperature ranging from room temperature to the boiling point of the mixture, optionally under pressure.

As a ketone preferably acetone, methyl ethyl ketone or methyl isobutyl ketone, particularly acetone is used. The molar ratio of the reactant related to acetoanil is generally ranging from 0.5 mole to a several fold excess. Preferably a 10 fold excess, is used.

The other starting material used according to the invention is 2,2,4-trimethyl-1,2-dihydro-quinoline and the compound is known from Bayer, J. Prakt. Chem. 2/33, 401/1886, and Combes, Bull. Soc. Chim. Fr. 49, 89 (1888).

5           The ketone condensation products of the invention are novel compounds. Due to their chemical structure they do not show a colourizing effect and can be used in a wide spectrum as antioxidant in the field of industry, food industry and  
10           fodder industry as well as in the field of therapy and veterinary science. The property of the new compounds by which they increase the activity of known coccidiostatics is particularly significant.

          We have found for instance that 2,2-di(2',2',4'-trimethyl-1',2'-dihydroquinolin-6'-yl)-propane shows an excellent  
15           rubber antiageing activity and does not cause colouration. Similarly 2,2-di(2',2',4'-trimethyl-1',2'-dihydro-quinoline)-butane can be used as a non-colourizing rubber antiageing agent as it is dissolved extremely well in rubber mixtures and it can be administered even at 5 % to products being contact  
20           with food.

          2,2-di(2',2'-dimethyl-4'-sodium-methane sulfonate-1',2'-dihydroquinolin-6'-yl)-propane is well soluble in water and can be consequently well applied in the form of injection  
25           in human therapy. The compound prevents the organism from detrimental free radical reactions. This is significant in case of poisoning, radiation injuries and disturbances of the circulation. In veterinary therapy encelophalomalattia in



poultry keeping can be treated when administered the compound into the drinking water.

5 Out of the tested new antioxidant active ingredients the toxicity of 2,2-di(2',2',4'-trimethyl-1,2',2'-dihydro-quinoline)-propane is very low and it can be well applied for foddering, and food industrial and therapeutical purposes and for stabilizing organisms, as well as in animal fodders, especially as antioxidants in poultry, rabbit and pig fodders and as activity increasing components of coccidiostatics.

10 Even under extreme conditions (in the presence of iron, copper compounds or halides) no decolourization occurs in the nutrient or in fatty tissues.

In order to prove the coccidiostatic activity

15 increasing effect of the compound according to Example 3 it was compared with Salinomycin<sup>R</sup> and Monensin<sup>R</sup>. The infectedness of the animals was evaluated by 0, 1, 2, 3 crosses (+, ++, +++). The oocysta index consists of the sum of the crosses related to the total number of the animals.

20

25

Table 1

Diet	oocysta index	death	body weight	standard deviation
Infected control	30/10	2	145	41
Compound according to Example 3, 60 ppm O Salinomycin <sup>x</sup>	10/10	-	165	31
Compound according to Example 3, 30 ppm	30/10	3	141	27
Compound according to Example 3, Salinomycin, 120 ppm, 30 ppm	0/10	-	126	20
Compound according to Example 3, Salinomycin, 120 ppm, 15 ppm	0/10	-	141	20
Compound according to Example 3, Monensin <sup>xx</sup> , 120 ppm, 30 ppm	0/10	-	144	25

<sup>x</sup> Hoechst

<sup>xx</sup> Eli Lilly

The table shows that in case of Salinomycin<sup>R</sup> the compound of Example 3 in a dose of 15 ppm gives the same protection, in case of Monensin the same compound at a dose of 30 ppm gives the same protection as the known compound administered per se at a dose recommended by the manufacturer.

The oocysta index is determined by a known method: the oocystas are counted microscopically. 25 visual fields are tested at the same time. If the number of the oocystas counted per field is below 1, then the value is marked by +, if it is between 1-10, it is marked by ++, above 10 the value is marked by +++.

- 9 -

## Antioxidant activity

On the basis of active oxygen method (AOM)

## 1. Description of the method

5 Under thermostatic conditions a uniform stream of air is passed through the samples containing and not containing antioxidant. The change of Lea-number by time is measured.

## 2. Used materials

10 Glicerol trioleate purum  $C_{57}H_{104}O_6$  LOBA FEINCHEMIE  
K.J. p. a.

Chloroform

Glacial acetic acid

 $Na_2S_2O_3$  0.002 N solution

15 Starch indicator

## 3. Test method

20 To 4 thermostated test cuvettes 30 g of glycerol trioleate are weighed in, in which 20 mg (0.02 %) test-antioxidant had been dissolved. The cuvettes are maintained at 70 °C and air is passed through the test oil at a velocity of 9.6-10 l/hour. Sample is taken every hour from the control and every 4 hour from the antioxidant samples and Lea-number is  
25 measured as follows:

To about 1 g sample 30 ml of a solution of an 1:1 chloroform and glacial acetic acid and 1 g solid potassium iodide is added, it is boiled for 60 sec, rapidly cooled and

- 10 -

15 ml of a 5 % aqueous potassium iodide solution is added.

It is titrated with 0.002 N  $\text{Na}_2\text{S}_2\text{O}_3$  solution in the presence of a starch indicator.

(Consumption/ml 0.002 N  $\text{Na}_2\text{S}_2\text{O}_3$ )-blank test x factor

weighing in (g)

#### 4. Results

##### 4/1. control

Time (h)	1	2	3	4	5	6	7	8	9	10	11	12
Lea number	12.4	24.9	21.6	24.3	38.4	37.3	52.4	63.3	80.0	85.3	108	111

##### 4/2. Samples

Time (h)	4	8	12	16	20	24	28	31	34
MTDQ comparative 6,6'-methylene-bis- derivative (Melting point 156 °C)	17.1	22.2	26.0	29.2	32.4	42.5	55.1	73.3	95.7
80 % material according to Example 2	20.2	19.3	18.6	25.2	29.4	36.6	44.5	58.4	64.9
98 % material according to Example 4	16.3	19.4	21.0	23.5	38.5	32.0	39.1	46.3	60.8
acetyl derivative according to Example 7	16.9	23.2	27.8	33.0	42.6	69.2	103.5		

In case of  $X=SO_3Na$  a watersoluble antioxidant is obtained, which is tested in the following heterogeneous system:

- 5      30 ml water neutralized with 1 ml phosphate puffer of pH=7.  
       20 g glycerol trioleate, 1.5 g 30 % fatty alcohol sulphonate.  
       20 g of the tested antioxidant agent are added to the emulsion thus prepared. The weighing in of the antioxidant and the Lea numbers are related to the oil content.

10

Lea number/time		0	2	4	6	8	10	12
15	Control	2.8	6.6	9.0	26.9	72.9	124.1	267.3
	$SO_3Na^+$ - derivative	2.8	3.7	6.1	10.9	28.0	45.0	93.7
	Glutathion	2.8	3.3	4.7	9.1	16.3	34.1	51.6
	L-ascorbic acid	2.8	8.8	32.6	69.6	103.0	132.0	193.0

20

## EXAMPLES

Example 1

To four necked flask equipped with a stirrer and a  
5 thermometer, a feeding funnel and reflux 150 parts by weight  
of acetone containing 10 % water, 105 parts by weight of  
acetanil, 2.5 parts by weight of pyridine are added and 100  
parts by weight of concentrated hydrochloric acid is added  
dropwise. The mixture is heated to boiling point and stirred  
10 for 22 hours at this temperature. The mixture is cooled,  
whereafter 110 parts by weight of 40 % sodium hydroxide is  
added. The mixture is stirred under boiling, acetone is  
separated and 40 parts by weight of unreacted acetanil are  
distilled off in vacuo. The bottom product is (60 parts by  
15 weight) of 2,2-di(2',2',4'-trimethyl-1',2'-dihydro-quinol-6'-  
yl)-propane of 80 % purity. Melting point: 125-135 °C.

Example 2

To an autoclave which can be heated by steam and  
20 cooled by water and equipped with a thermometer, stirrer and  
a feeding opening 100 parts by weight of acetanil, 2 parts  
by weight of triethanol amine, 280 parts by weight of  
anhydrous acetone 106 parts by weight of concentrated  
hydrochloric acid are added. The equipment is closed and the  
25 content is stirred under pressure for 12 hours at 72-75 °C,  
then it is cooled to 40 °C and neutralized by adding 100 parts  
by weight of 40 % sodium hydroxide solution. The aqueous layer  
is removed and from the organic layer acetone is removed,

- 13 -

whereafter acetoanil is distilled off in vacuo. Yield: 62 parts by weight of 78 % 2,2-di(2',2',4'-trimethyl-1',2'-dihydro-quinol-6'-yl)-propane. Melting point: 120-135 °C.

5

### Example 3

From the antioxidant according to Example 1 and 2 a product is obtained in a good yield which can be recrystallized from benzene, then from isopropanol, which  
10 melts at 156 °C, is completely white and the purity of which is 96 % according to HPLC chromatography. The product shows a biological activity similar to that of the product of purity 80 %. By evaporating the mother liquor an excellent rubber  
ageing inhibitor is obtained.

15

### Example 4

One may proceed according to Example 1 but acetone is replaced by methyl ethyl ketone. Yield: 45 parts by weight of 2,2-di(2',2',4'-trimethyl-1',2'-dihydro-quinol-6'-yl)-butane,  
20 purity: 55 %. After recrystallization from hexane followed by isopropanol a product of purity 96-97 % is obtained melting at 117-118 °C. The product is an excellent antioxidant and its synergistic effect makes a 80 % saving possible when used together with coccidiostatics. From the mother liquor a non-  
25 colourizing antioxidant for rubber industry can be obtained.

Example 5

One may proceed as disclosed in Example 1 but as a ketone methyl isobutyl ketone is used. Yield: 20 % 2,2-di(2',2',4'-trimethyl-1',2'-dihydro-quinol-6'-yl)-isohexane. Purity: 50 %, melting point after recrystallization: 120-126 °C. The product can be used similarly like the product in Example 4.

Example 6

100 parts by weight of a 96 % product according to Example 3 are dissolved in 400 parts by weight of 96 % sulfuric acid, whereafter the mixture is slowly heated to 80 °C and the reaction is performed for 2-3 hours at this temperature. The sulfonated product is added dropwise to a mixture of 1000 parts by weight of water and 1000 parts by weight of ice and the precipitated sulfonic acid is filtered. It is recrystallized from hot water in the form of free acid and then converted to sodium salt. The thus obtained colourless crystalline product is dried to constant weight. Yield: 105 parts by weight.

Analysis of the product dried at 120 °C:

C 55.1 % (54.91); H (5.4 % (5.42); N 4.56 % (4.75); O 16.34 % (16.27) S 10.9 % (10.85); Na 7.7 % (7.8).

The product is suitable for therapeutical purposes.

Example 7

The product of Example 3 is used. 100 parts by weight of this product are dissolved in 600 parts by weight of acetic




- 15 -

anhydride and the solution is heated for 2 hours under reflux. Acetic acid and the excess of the anhydride are distilled off from the crude product and it is recrystallized from 600 parts by weight of hot acetone. Yield: 114 parts by weight, melting point: 120-121 °C, and the product is obtained in the form of pale yellow crystals.

## Claims:

## 1. Compounds of the general Formula I



and acid addition salts thereof - wherein

10  $R^1$  stands for optionally substituted  $C_{1-4}$  alkyl and

$R^2$  stands for optionally substituted  $C_{1-2}$  alkyl,

X stands for hydrogen or  $SO_3Me$  - wherein

Me stands for hydrogen, alkali or alkali earth metal ion,

15 Y stands for hydrogen or acyl.

## 2. Compounds as claimed in Claim 1

$R^1$  stands for optionally substituted  $C_{1-4}$  alkyl and

$R^2$  stands for optionally substituted  $C_{1-2}$  alkyl,

20 X stands for hydrogen and

Y stands for hydrogen.

3. Process for the preparation of the compounds of the general Formula I and acid addition salts thereof, which comprises condensing 2,2,4-trimethyl-1,2-dihydro-quinoline or a salt thereof with a ketone of the general Formula  $R_1R_2CO$  - wherein  $R_1$  and  $R_2$  are as stated above - in the presence of a catalyst, such as mineral acid, preferably hydrochloric acid

25

- 17 -

and of a cocatalyst, such as nitrogen-containing base,  
preferably triethanol amine, pyridine or aniline in a solvent  
and if desired converting the obtained product to acid  
addition salt or setting free the base from the salt and if  
5 desired sulfonating and/or acylating the obtained base.

4. Process as claimed in Claim 3, which comprises  
performing the condensation in an 0-40 %, preferably 10-20 %  
of the ketone.

10 5. Process as claimed in Claim 3, which comprises  
using the acid preferably hydrochloric acid in a molar ratio  
of 0.9-2.5 mole, preferably 1.25-1.75 mole.

15 6. Pharmaceutical composition comprising as active  
ingredient a compound as claimed in Claim 1.

7. Fodder or fodder premix for the treatment of  
coccidiosis, which comprises a compound as claimed in Claim 2  
20 next to ionophoric polyether antibiotics or salts thereof,  
preferably sodium salts.

25

# INTERNATIONAL SEARCH REPORT

International Application No PCT/HU 88/00026

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 07 D 215/06, 215/08, 215/12; A 61 K 31/47; A 23 K 3/00														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched *</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">Int.Cl.<sup>4</sup></td> <td style="padding: 5px;">C 07 D 215/06, 215/08, 215/12</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *</div> <div style="text-align: center; padding: 10px 0;">AT</div>			Classification System	Classification Symbols	Int.Cl. <sup>4</sup>	C 07 D 215/06, 215/08, 215/12								
Classification System	Classification Symbols													
Int.Cl. <sup>4</sup>	C 07 D 215/06, 215/08, 215/12													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT *</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category *</th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document, ** with indication, where appropriate, of the relevant passages <sup>13</sup></th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No. <sup>12</sup></th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="vertical-align: top; padding: 5px;">DE, A1, 3 025 656 (MATERIAL VEG.) 22 January 1981 (22.01.81), see claims 1, 6, 10.</td> <td style="vertical-align: top; text-align: center; padding: 5px;">(1, 3, 6, 7)</td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="vertical-align: top; padding: 5px;">DE, A1, 2 243 777 (MATERIAL VEG.) 22 March 1973 (22.03.73), see claims 1-3, 6.</td> <td style="vertical-align: top; text-align: center; padding: 5px;">(1, 3, 6, 7)</td> </tr> <tr> <td colspan="3" style="text-align: center; padding: 10px 0;">-----</td> </tr> </table>			Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages <sup>13</sup>	Relevant to Claim No. <sup>12</sup>	A	DE, A1, 3 025 656 (MATERIAL VEG.) 22 January 1981 (22.01.81), see claims 1, 6, 10.	(1, 3, 6, 7)	A	DE, A1, 2 243 777 (MATERIAL VEG.) 22 March 1973 (22.03.73), see claims 1-3, 6.	(1, 3, 6, 7)	-----		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages <sup>13</sup>	Relevant to Claim No. <sup>12</sup>												
A	DE, A1, 3 025 656 (MATERIAL VEG.) 22 January 1981 (22.01.81), see claims 1, 6, 10.	(1, 3, 6, 7)												
A	DE, A1, 2 243 777 (MATERIAL VEG.) 22 March 1973 (22.03.73), see claims 1-3, 6.	(1, 3, 6, 7)												
-----														
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="padding: 5px;">05 July 1988 (05.07.88)</td> <td style="padding: 5px;">12 July 1988 (12.07.88)</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px;">AUSTRIAN PATENT OFFICE</td> <td style="padding: 5px; text-align: center;"> </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	05 July 1988 (05.07.88)	12 July 1988 (12.07.88)	International Searching Authority	Signature of Authorized Officer	AUSTRIAN PATENT OFFICE					
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
05 July 1988 (05.07.88)	12 July 1988 (12.07.88)													
International Searching Authority	Signature of Authorized Officer													
AUSTRIAN PATENT OFFICE														

Anhang zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentedokumente angegeben. Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

Annex to the International Search Report on International Patent Application No. PCT/HU 88/00026

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned International search report. The Austrian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Annexe au rapport de recherche internationale relatif à la demande de brevet international n°.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche internationale visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office autrichien des brevets.

Im Recherchenbericht angeführtes Patent- dokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
DE-A1-3 025 656	22/01/1981	AR-A1- 223 884 AT-A - 3 544/80 AT-B - 375 647 BE-A1- 884 187 BR-A - 8 004 170 CA-A1- 1 138 873 CH-A - 649 536 CS-P - 227 309 CS-P - 227 333 CS-B2- 227 309 DD-C - 151 872 DK-A - 2 880/80 FI-A - 802 153 FI-B - 75 809 FR-A1- 2 460 933 FR-B1- 2 460 933 GB-A1- 2 054 582 GB-B2- 2 054 582 HU-B - 185 208 IT-A - 1 132 511 JP-A2-56-039 070 JP-A2-62-187 457 NL-A - 8 003 839 PL-A1- 225 476 PL-A1- 232 265 PL-B1- 125 177 PL-B1- 126 791 SE-A - 8 004 973 SE-B - 447 899 SE-C - 447 899 SU-A3- 990 083 SU-A1- 1 108 092 US-A - 4 356 306 US-A - 4 510 147	30/09/1981 15/01/1984 27/08/1984 03/11/1980 21/01/1981 04/01/1983 31/05/1985 16/04/1984 16/04/1984 16/04/1984 11/11/1981 07/01/1981 07/01/1981 29/04/1988 30/01/1981 12/07/1985 18/02/1981 14/09/1983 28/12/1984 02/07/1986 14/04/1981 15/08/1987 08/01/1981 27/11/1981 29/03/1982 30/04/1983 31/08/1983 07/01/1981 22/12/1986 02/04/1987 15/01/1983 15/08/1984 26/10/1982 09/04/1985

			YU-A -	1	741/80	30/09/1983
DE-A1-2	243 777	22/03/1973	AT-B -	319	250	10/12/1974
-B2-		03/05/1978	AU-A1-	46	298/72	14/03/1974
-C3-		04/01/1979	BE-A1-	788	509	02/01/1973
			BG-D -	19	596	25/06/1975
			CA-A1-	992	546	06/07/1976
			CH-A -	580	079	30/09/1976
			CS-P -	170	505	27/08/1976
			DD-C -	101	667	12/11/1973
			DE-C2-	2	265 400	08/04/1982
			DE-C2-	2	265 399	04/10/1984
			DK-A -		441/75	04/08/1975
			DK-B -	135	990	25/07/1977
			DK-C -	135	990	27/12/1977
			DK-B -	149	332	05/05/1986
			DK-C -	149	332	24/11/1986
			ES-A1-	406	433	16/01/1976
			ES-A1-	435	497	16/04/1977
			ES-A5-	435	497	16/05/1977
			FR-A1-	2	154 469	11/05/1973
			FR-B1-	2	154 469	05/03/1976
			GB-A -	1	390 991	16/04/1975
			HU-P -	162	358	28/02/1973
			IT-A -	1	022 011	20/03/1978
			JP-A2-48	061	483	28/08/1973
			JP-B4-53-046	839		16/12/1978
			JP-A2-54-067	576		31/05/1979
			JP-B4-59-040	179		28/09/1984
			NL-A -	7	212 192	09/03/1973
			NL-B -	174	721	01/03/1984
			NL-C -	174	721	01/08/1984
			SE-A -	7	503 840	03/04/1975
			SE-B -	393	982	31/05/1977
			SE-C -	393	982	08/09/1977
			SE-B -	434	050	02/07/1984
			SE-C -	434	050	11/10/1984
			SU-D -	520	045	30/06/1976
			US-A -	4	025 631	24/05/1977
			US-A -	4	046 765	06/09/1977
			YU-A -	2	257/72	28/02/1982
			ZA-A -	7	205 777	26/09/1973